Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04818229




Registration number
NCT04818229
Ethics application status
Date submitted
24/03/2021
Date registered
26/03/2021
Date last updated
21/04/2022

Titles & IDs
Public title
A Study to Investigate the Effects of CBP-307 on the Heart Rate-corrected QT Interval (QTc) in Healthy Subjects
Scientific title
A Phase I, Multicenter, Randomized, Double-blind, Double-dummy, Placebo- and Positive-Controlled Study to Investigate the Effects of CBP-307 on the QTc Interval in Healthy Subjects
Secondary ID [1] 0 0
CBP-307AU002
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Autoimmune Diseases 0 0
Condition category
Condition code
Inflammatory and Immune System 0 0 0 0
Autoimmune diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - CBP-307
Treatment: Drugs - Placebo-matched CBP-307
Treatment: Drugs - Moxifloxacin (Avelox)
Treatment: Drugs - Placebo-matched Moxifloxacin

Experimental: Investigational Group 1 - Therapeutic and supratherapeutic multiple oral doses of CBP-307.

Placebo Comparator: Investigational Group 2A - Moxifloxacin (positive control for method validation) and Placebo oral administration.

Placebo Comparator: Investigational Group 2B - Moxifloxacin (positive control for method validation) and Placebo oral administration.


Treatment: Drugs: CBP-307
CBP-307 capsules oral administration.

Treatment: Drugs: Placebo-matched CBP-307
Placebo-matched CBP-307 capsules oral administration.

Treatment: Drugs: Moxifloxacin (Avelox)
Moxifloxacin tablets oral administration?

Treatment: Drugs: Placebo-matched Moxifloxacin
Placebo-matched Moxifloxacin tablets oral administration.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change-from-baseline QT interval corrected for heart rate using Fridericia's method (QTcF)
Timepoint [1] 0 0
From Baseline to Day 16
Secondary outcome [1] 0 0
Change-from-baseline heart rate (HR)
Timepoint [1] 0 0
From Baseline to Day 16
Secondary outcome [2] 0 0
Change-from-baseline PR
Timepoint [2] 0 0
From Baseline to Day 16
Secondary outcome [3] 0 0
Change-from-baseline QRS
Timepoint [3] 0 0
From Baseline to Day 16
Secondary outcome [4] 0 0
Placebo-corrected change-from-baseline HR
Timepoint [4] 0 0
From Baseline to Day 16
Secondary outcome [5] 0 0
Placebo-corrected change-from-baseline QTcF
Timepoint [5] 0 0
From Baseline to Day 16
Secondary outcome [6] 0 0
Placebo-corrected change-from-baseline PR
Timepoint [6] 0 0
From Baseline to Day 16
Secondary outcome [7] 0 0
Placebo-corrected change-from-baseline QRS
Timepoint [7] 0 0
From Baseline to Day 16
Secondary outcome [8] 0 0
Categorical outliers for QTcF
Timepoint [8] 0 0
From Baseline to Day 16
Secondary outcome [9] 0 0
Categorical outliers for HR
Timepoint [9] 0 0
From Baseline to Day 16
Secondary outcome [10] 0 0
Categorical outliers for PR
Timepoint [10] 0 0
From Baseline to Day 16
Secondary outcome [11] 0 0
Categorical outliers for QRS
Timepoint [11] 0 0
From Baseline to Day 16
Secondary outcome [12] 0 0
Frequency of treatment-emergent changes of T-wave morphology
Timepoint [12] 0 0
From Baseline to Day 16
Secondary outcome [13] 0 0
Frequency of treatment-emergent changes of U-wave presence
Timepoint [13] 0 0
From Baseline to Day 16
Secondary outcome [14] 0 0
Area under the concentration-time curve from time zero extrapolated to infinity (AUCinf)
Timepoint [14] 0 0
From Baseline to Day 29 ± 2
Secondary outcome [15] 0 0
Area under the concentration-time curve from time zero to 24 hours postdose (AUC0-24)
Timepoint [15] 0 0
From Baseline to Day 29 ± 2
Secondary outcome [16] 0 0
Maximum observed concentration (Cmax)
Timepoint [16] 0 0
From Baseline to Day 29 ± 2
Secondary outcome [17] 0 0
Time of the maximum observed concentration (tmax)
Timepoint [17] 0 0
From Baseline to Day 29 ± 2
Secondary outcome [18] 0 0
Incidence and severity of Adverse Event (AE)
Timepoint [18] 0 0
From Baseline to Day 29 ± 2

Eligibility
Key inclusion criteria
1. Males or females, of any race, between 18 and 60 years of age, inclusive.

2. Body mass index between 18.0 and 30.0 kg/mE2, inclusive.

3. In good health, determined by no clinically significant findings from medical history,
physical examination, 12-lead ECG, vital signs measurements, and clinical laboratory
evaluations (congenital nonhemolytic hyperbilirubinemia [eg, suspicion of Gilbert's
syndrome based on total and direct bilirubin] is not acceptable) at screening and
confirmed at check-in as assessed by the investigator (or designee).

4. Females will not be pregnant or lactating, and females of childbearing potential and
males will agree to use contraception. Negative pregnancy test for females of
childbearing potential at screening (blood test) and check-in (urine test).

5. Supine diastolic blood pressure between 60 and 90 mmHg and systolic blood pressure
between 90 and 140 mmHg (inclusive) at screening on a single measurement (confirmed by
a single repeat, if necessary) following at least 5 minutes of rest.

6. No clinically significant history or presence of ECG findings as judged by the
investigator at screening and check-in, including each criterion as listed below:

1. Normal sinus rhythm (HR between 55 bpm and 100 bpm inclusive);

2. QTcF interval =450 msec for males and females;

3. QRS interval =110 msec; and confirmed by manual over-read if >110 msec;

4. PR interval =200 msec.

7. Has serum potassium, calcium, and magnesium levels within the normal reference range
at screening, as judged by the investigator.

8. Able to swallow multiple tablets (based on subject's verbal confirmation).

9. Able to comprehend and willing to sign an ICF and to abide by the study restrictions.
Minimum age
18 Years
Maximum age
60 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
-

Subjects will be excluded from the study if they satisfy any of the following criteria at
the screening visit unless otherwise stated:

1. Subject is mentally or legally incapacitated or has had significant history of recent
mental health issues requiring medication and/or hospitalization at the time of the
screening visit or expected during the conduct of the study.

2. Significant history or clinical manifestation of any metabolic, allergic,
dermatological, hepatic, renal, hematological, pulmonary, cardiovascular,
gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as
determined by the investigator (or designee). Note: Childhood asthma that is
considered recovered or seasonal allergies that are not currently active or requiring
treatment are allowed.

3. History of significant hypersensitivity, intolerance, or allergy to any drug compound,
food, or other substance, unless approved by the investigator (or designee).

4. History or presence of hypersensitivity or idiosyncratic reaction to the study drugs,
related compounds, or inactive ingredients.

5. History of significant multiple and/or severe allergies (eg, latex allergy, band-aids,
adhesive dressing, or medical tape), or has had an anaphylactic reaction or
significant intolerability to prescription or nonprescription drugs.

6. History of stomach or intestinal surgery or resection that would potentially alter
absorption and/or excretion of orally administered drugs within 6 months prior to the
first dose of study drug (uncomplicated appendectomy and hernia repair will be
allowed).

7. History or presence of:

1. Hypokalemia, in the opinion of the investigator (or designee);

2. Risk factors for Torsades de Pointes (eg, heart failure, cardiomyopathy, or
family history of Long QT Syndrome);

3. Sick sinus syndrome, second, or third degree atrioventricular block, myocardial
infarction, pulmonary congestion, cardiac arrhythmia, prolonged QT interval, or
conduction abnormalities;

4. Repeated or frequent syncope or vasovagal episodes;

5. Hypertension, angina, bradycardia, or severe peripheral arterial circulatory
disorders.

8. Clinically significant abnormalities (as judged by the investigator in laboratory
tests results [out-of-range results confirmed on repeat]), including but not limited
to the following parameters:

1. alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, or
total bilirubin greater than 1.5 × upper limit of normal;

2. hemoglobin <10 g/dL, WBC <3.0 ×10E9/L, neutrophils <1.5 ×10E9/L, lymphocytes <0.8
×10E9/L and platelets <100 ×10E9/L or >1200 × 10E9/L;

9. History or evidence of alcoholism or drug/chemical abuse within 2 years prior to
check-in.

10. Alcohol consumption of >10 units per week for males and females. One unit of alcohol
equals ½ pint (285 mL) of beer or lager, 1 glass (125 mL) of wine, or 1/6 gill (25 mL)
of spirits.

11. Positive alcohol breath test result or positive urine drug screen (confirmed by
repeat) at screening or check-in.

12. Positive hepatitis panel, positive syphilis test, and/or positive human
immunodeficiency virus test.

13. Participation in a clinical study involving administration of an investigational drug
(new chemical entity) in the past 28 days prior to the first dose of study treatment
on Day 1. The 28-day window will be derived from the date of the last blood collection
or dosing, whichever is later, in the previous study to Day 1 of the current study.

14. Participation in a previous clinical study where subjects received CBP-307.

15. Administration of a Coronavirus Disease 2019 (COVID-19) vaccine in the past 28 days
prior to first dose of study treatment on Day 1.

16. Use or intend to use any prescription medications/products within 14 days prior to
first dose of study drug (Day 1) and throughout the study, unless deemed acceptable by
the investigator (or designee). Note: For females only, the use hormonal
contraception, hormone replacement therapy or oral, implantable, transdermal,
injectable, or intrauterine hormonal contraceptives within 14 days prior to Day 1 is
not acceptable, except for Mirena®.

17. Use or intend to use any drugs known to be significant inhibitors or inducers of CYP
enzymes and/or P-gp, including St. John's Wort, for days prior to the first dose of
study drug and throughout the study. Appropriate sources will be consulted by the
investigator or designee to confirm the lack of PK/PD interaction with the study drug.

18. Use or intend to use slow-release medications/products considered to still be active
within 14 days prior to check-in, unless deemed acceptable by the investigator (or
designee).

19. Use or intend to use any nonprescription medications/products including antacids,
vitamins (especially those containing magnesium, aluminum, iron, or zinc), minerals,
and phytotherapeutic/herbal/plant-derived preparations within 14 days prior to
check-in, unless deemed acceptable by the investigator (or designee).

20. Use of tobacco- or nicotine-containing products within 3 months prior to check-in, or
positive cotinine at screening or check-in.

21. Has been on a diet incompatible with the on-study diet (including an extreme diet
which resulted in a significant weight change for whatever reason), in the opinion of
the investigator, within the 28 days prior to the first dose of study treatment, and
throughout the study.

22. Consumption of caffeine/xanthine-containing foods or beverages within 48 hours prior
to check-in until discharge.

23. Ingestion of poppy seed-, Seville orange-, or grapefruit-containing foods or beverages
within 7 days prior to check-in.

24. Receipt of blood products within 2 months prior to check-in.

25. Donation of blood from 3 months prior to screening, plasma from 2 weeks prior to
screening, or platelets from 6 weeks prior to screening.

26. Poor peripheral venous access.

27. Subjects who, in the opinion of the investigator (or designee), should not participate
in this study.

Study design
Purpose of the study
Basic Science
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/06/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
30/03/2022
Sample size
Target
Accrual to date
Final
112
Recruitment in Australia
Recruitment state(s)
SA
Recruitment hospital [1] 0 0
CMAX - Adelaide
Recruitment postcode(s) [1] 0 0
5000 - Adelaide
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Florida

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Connect Biopharma Australia Pty Ltd
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study will investigate the effects of therapeutic and supratherapeutic oral doses of
CBP-307 on the QTc interval in healthy subjects.
Trial website
https://clinicaltrials.gov/ct2/show/NCT04818229
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Australia Connect
Address 0 0
Connect Biopharma Australia Pty Ltd
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04818229